Postępy Psychiatrii i Neurologii
eISSN: 2720-5371
ISSN: 1230-2813
Advances in Psychiatry and Neurology/Postępy Psychiatrii i Neurologii
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Recenzenci Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac Opłaty publikacyjne Standardy etyczne i procedury
Panel Redakcyjny
Zgłaszanie i recenzowanie prac online
SCImago Journal & Country Rank
Wyszukiwanie
Zasady redakcyjne
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Bez opłat za publikację

without publication fees

Otwarty dostęp

without publication fees
4/2025
vol. 34
 
Poleć ten artykuł:
Wyślij znajomemu
Udostępnij:
Opis przypadku

Late-onset myelin oligodendrocyte glycoprotein antibody-associated disease: an underrecognized entity in clinical practice; what does its course in later life teach us? A case report and narrative review

Michalina Rzepka
1, 2
,
Mateusz Toś
1, 2
,
Piotr T. Oleksy
3
,
Magdalena Reclik
3
,
Zuzanna Mularczyk
3
,
Aleksandra Śmigiel
3
,
Magdalena Błaszczyk
2
,
Joanna Siuda
1, 2

  1. Department of Neurology, Faculty of Medical Sciences in Katowice, Medical University of Silesia in Katowice, Poland
  2. University Clinical Centre of K. Gibiński, Katowice, Poland
  3. Students’ Scientific Association, Department of Neurology, Faculty of Medical Sciences in Katowice, Medical University of Silesia in Katowice, Poland
DOI: https://doi.org/10.5114/ppn.2025.156790
Data publikacji online: 2025/12/08
Pliki artykułu:
- PPiN-00527_Late-onset.pdf  [0.99 MB]
- Supplementary Figure 1.pdf  [0.26 MB]
- Supplementary Table S1.pdf  [0.20 MB]
Pobierz cytowanie
 
Metryki PlumX:
 
1. Ambrosius W, Michalak S, Kozubski W, Kalinowska A. Myelin oligodendrocyte glycoprotein antibody-associated disease: current insights into the disease pathophysiology, diagnosis and management. Int J Mol Sci 2021; 22: 100. DOI: https://doi.org/10.3390/ijms22010100.
2. Banwell B, Bennett JL, Marignier R, Kim HJ, Brilot F, Flanagan EP, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol 2023; 22: 268-282.
3. Hor JY, Fujihara K. Epidemiology of myelin oligodendrocyte glycoprotein antibody-associated disease: a review of prevalence and incidence worldwide. Front Neurol 2023; 14: 1260358. DOI: 10.3389/fneur.2023.1260358.
4. Cobo-Calvo A, Ruiz A, Rollot F, Arrambide G, Deschamps R, Maillart E, et al. Clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody-associated disease. Ann Neurol 2021; 89: 30-41.
5. Huang Y, Luo W, Cheng X, Sun X, Wang Y, Shu Y, et al. Clinical and imaging features of patients with late-onset myelin oligodendrocyte glycoprotein antibody-associated disease. Mult Scler Relat Disord 2024; 82: 105405. DOI: 10.1016/j.msard.2023.105405.
6. Fan Y, Wang Z, Wu Y, Zhou L, Wang L, Huang W, et al. Fewer relapses and worse outcomes of patients with late-onset myelin oligodendrocyte glycoprotein antibody-associated disease. J Neurol Neurosurg Psychiatry 2025; 96: 655-664.
7. Varley JA, Champsas D, Prossor T, Pontillo G, Abdel-Mannan O, Khaleeli Z, et al. Validation of the 2023 international diagnostic criteria for MOGAD in a selected cohort of adults and children. Neurology 2024; 103: e209321. DOI: 10.1212/WNL.0000000000209321.
8. Fonseca E, Olivé-Cirera G, Martinez-Hernandez E, Guasp M, Naranjo L, Ruiz-García R, et al. Investigating the 2023 MOGAD criteria in children and adults with MOG-antibody positivity within and outside attacks. Neurology 2024; 103: e209682. DOI: 10.1212/WNL.0000000000209682.
9. Cai MT, Hua Y, Lai QL, Su SY, Shen CH, Qiao S, et al. Performance of the 2023 diagnostic criteria for MOGAD: real-world application in a Chinese multicenter cohort of pediatric and adult patients. BMC Med 2025; 23: 40. DOI: 10.1186/s12916-025-03875-9.
10. Habbestad A, Willumsen JS, Aarseth JH, Grytten N, Midgard R, Wergeland S, et al. Increasing age of multiple sclerosis onset from 1920 to 2022: a population-based study. J Neurol 2024; 271: 1610-1617.
11. Grytten N, Aarseth JH, Lunde HMB, Myhr KM. A 60-year follow-up of the incidence and prevalence of multiple sclerosis in Hordaland County, Western Norway. J Neurol Neurosurg Psychiatry 2016; 87: 100-105.
12. Engelhard J, Oleske DM, Schmitting S, Wells KE, Talapala S, Barbato LM. Multiple sclerosis by phenotype in Germany. Mult Scler Relat Disord 2022; 57: 103326. DOI: 10.1016/j.msard.2021.103326.
13. Cai LJ, Zhang Q, Zhang Y, Chen HX, Shi ZY, Du Q, Zhou HY. Clinical characteristics of very late-onset neuromyelitis optica spectrum disorder. Mult Scler Relat Disord 2020; 46: 102515. DOI: 10.1016/j.msard.2020.102515.
14. Koch-Henriksen N, Thygesen LC, Stenager E, Laursen B, Magyari M. Incidence of MS has increased markedly over six decades in Denmark particularly with late onset and in women. Neurology 2018; 90: e1954-e1963. DOI: 10.1212/WNL.0000000000005612.
15. Zhang LJ, Yang LN, Li T, Wang J, Qi Y, Zhang DQ, et al. Distinctive characteristics of early-onset and late-onset neuromyelitis optica spectrum disorders. Int J Neurosci 2017; 127: 334-338.
16. Du Y, Xiao L, Ding Z, Huang K, Xiao B, Feng L. MOGAD involving cranial neuropathies: a case report and review of literature. Brain Sci 2022; 12: 1529. DOI: 10.3390/brainsci12111529.
17. Deschamps R, Poillon G, Marill A, Marignier R, Gout O, Sene T. Myelin oligodendrocyte glycoprotein antibody-associated diffuse orbital inflammation. Mult Scler 2020; 26: 1441-1443.
18. Teru SS, Dogiparthi J, Bonitz TJ, Buzas C. Myelin oligodendrocyte glycoprotein antibody-associated disease: a case report. Cureus 2024; 16: e55652. DOI: 10.7759/cureus.55652.
19. Jeyanathan B, Micieli J. Acute myelin oligodendrocyte glycoprotein-IgG optic neuritis without optic nerve enhancement. Case Rep Ophthalmol 2024; 16: 7-11.
20. Razali A, Zain A, Din N, Tan H, Ng C. MOG antibody-associated disease with recurrent optic neuritis and multiple cranial neuropathies: a rare clinical phenotype. Neurol India 2020; 68: 500. DOI: 10.4103/0028-3886.280641.
21. Santos E, Moura J, Samões R, Sousa AP, Mendonça T, Abreu P, et al. Late onset neuromyelitis optica spectrum disorders (LONMOSD) from a nationwide Portuguese study: anti-AQP4 positive, anti-MOG positive and seronegative subgroups. Mult Scler Relat Disord 2022; 63: 103845. DOI: 10.1016/j.msard.2022.103845.
22. Kim KH, Cho J, Shin HY, Kim SW. A case of anti-myelin oligodendrocyte glycoprotein antibody-positive late-onset acute disseminated encephalomyelitis. J Clin Neurol 2021; 17: 330. DOI: 10.3988/jcn.2021.17.2.330.
23. Mirmosayyeb O, Brand S, Barzegar M, Afshari-Safavi A, Nehzat N, Shaygannejad V, Bahmani DS. Clinical characteristics and disability progression of early-and late-onset multiple sclerosis compared to adult-onset multiple sclerosis. J Clin Med 2020; 9: 1326. DOI: 10.3390/jcm9051326.
24. Geraldes R, Esiri MM, DeLuca GC, Palace J. Age-related small vessel disease: a potential contributor to neurodegeneration in multiple sclerosis. Brain Pathol 2017, 27: 707-722.
25. Juryńczyk M, Jakuszyk P, Kurkowska-Jastrzębska I, Palace J. Increasing role of imaging in differentiating MS from non-MS and defining indeterminate borderline cases. Neurol Neurochir Pol 2022; 56: 210-219.
26. Szewczyk AK, Papuć E, Mitosek-Szewczyk K, Woś M, Rejdak K. NMOSD – diagnostic dilemmas leading towards final diagnosis. Brain Sci 2022; 12: 885. DOI:10.3390/brainsci12070885.
27. Pratt L, Meirson H, Shapira Rootman M, Ben-Sira L, Shiran SI. Radiological features in pediatric myelin oligodendrocyte glycoprotein antibody-associated disease – diagnostic criteria and lesion dynamics. Pediatr Radiol 2025; 55: 699-720.
28. Tom Mishael J, Sandeep S, George A, Philip B, Deepalam S. MRI features of myelin oligodendrocyte glycoprotein antibody disease: a descriptive study – how it differs from neuromyelitis optica spectrum disorders and multiple sclerosis. Egypt J Radiol Nucl Med 2023; 54: 17. DOI: 10.1186/s43055-023-01066-1.
29. Cacciaguerra L, Redenbaugh V, Chen JJ, Morris P, Sechi E, Syc-Mazurek SB, et al. Timing and predictors of T2-lesion resolution in patients with myelin oligodendrocyte glycoprotein antibody-associated disease. Neurology 2023; 101: e1376-e1381. DOI: 10.1212/WNL.0000000000207478.
30. Cacciaguerra L, Abdel-Mannan O, Champsas D, Mankad K, Krecke KN, Chen JJ, et al. Radiologic lag and brain MRI lesion dynamics during attacks in MOG antibody-associated disease. Neurology 2024; 102: e209303. DOI: 10.1212/WNL.0000000000209303.
31. Santoro A, Bientinesi E, Monti D. Immunosenescence and inflammaging in the aging process: age-related diseases or longevity? Ageing Res Rev 2021; 71: 101422. DOI: 10.1016/j.arr.2021.101422.
32. Grebenciucova E, Berger JR. Immunosenescence: the role of aging in the predisposition to neuro-infectious complications arising from the treatment of multiple sclerosis. Curr Neurol Neurosci Rep 2017, 17: 61. DOI: 10.1007/s11910-017-0771-9.
33. Jarius S, Pellkofer H, Siebert N, Korporal-Kuhnke M, Hümmert MW, Ringelstein M, et al. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients. J Neuroinflammation 2020; 17: 261. DOI: 10.1186/s12974-020-01824-2.
34. Farrall AJ, Wardlaw JM. Blood-brain barrier: ageing and microvascular disease – systematic review and meta-analysis. Neurobiol Aging 2009, 30: 337-352.
35. Chen JXY, Vipin A, Sandhu GK, Leow YJ, Zailan FZ, Tanoto P, et al. Blood-brain barrier integrity disruption is associated with both chronic vascular risk factors and white matter hyperintensities. J Prev Alzheimers Dis 2025; 12: 100029. DOI: 10.1016/j.tjpad.2024.100029.
36. Cobo-Calvo A, Sepúlveda M, Rollot F, Armangué T, Ruiz A, Maillart E, et al. Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. J Neuroinflammation 2019; 16: 134. DOI: 10.1186/s12974-019-1525-1.
37. Tomizawa Y, Hoshino Y, Kamo R, Cossu D, Yokoyama K, Hattori N. Comparing clinical and imaging features of patients with MOG antibody-positivity and with and without oligoclonal bands. Front Immunol 2023; 14: 1211776. DOI: 10.3389/fimmu.2023.1211776.
38. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation 2016; 13: 279. DOI: 10.1186/s12974-016-0717-1.
39. Forcadela M, Rocchi C, San Martin D, Gibbons EL, Wells D, Woodhall MR, et al. Timing of MOG-IgG testing is key to 2023 MOGAD diagnostic criteria. Neurol Neuroimmunol Neuroinflamm 2023; 11: e200183. DOI: 10.1212/NXI.0000000000200183.
40. Trewin BP, Brilot F, Reddel SW, Dale RC, Ramanathan S. MOGAD: a comprehensive review of clinicoradiological features, therapy and outcomes in 4699 patients globally. Autoimmun Rev 2025; 24: 103693. DOI: 10.1016/j.autrev.2024.103693.
41. Jurynczyk M, Messina S, Woodhall MR, Raza N, Everett R, Roca-Fernandez A, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK Study. Brain 2017; 140: 3128-3138.
42. Mouresan EF, Mentesidou E, Berglund A, Mckay KA, Hillert J, Iacobaeus E. Clinical characteristics and long-term outcomes of late-onset multiple sclerosis: a Swedish Nationwide Study. Neurology 2024; 102: e208051. DOI: 10.1212/WNL.0000000000208051.
43. Fragoso YD, Ruocco HH, Dias RM, Cabeça H, Gonçalves R, de Carvalho Sousa NA, et al. Late onset of neuromyelitis optica spectrum disorders. Neurol Ther 2019; 8: 477-482.
44. Ostolaza Ibáñez A, Corroza Laviñeta J, Ayuso Blanco T. Immunosenescence: the role of age in multiple sclerosis. Neurologia (Engl Ed) 2023, 38: 284-290.
45. Goyne CE, Fair AE, Sumowski PE, Graves JS. The impact of aging on multiple sclerosis. Curr Neurol Neurosci Rep 2024; 24: 83-93.
46. Ostolaza A, Corroza J, Ayuso T. Multiple sclerosis and aging: comorbidity and treatment challenges. Mult Scler Relat Disord 2021; 50: 102815. DOI: 10.1016/j.msard.2021.102815.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0). License allowing third parties to download and share its works but not commercially purposes or to create derivative works.
Termedia
O Wydawnictwie Oferty Newsletter Kontakt Praca
Polityka prywatności Polityka reklamowa Napisz do nas Nota prawna Regulamin
Na skróty
Mednauka Aktualności Czasopisma Książki eBooki Konferencje i webinary Podcasty
Serwisy
KONGRES TOP MEDICAL TRENDS Menedżer Zdrowia Lekarz POZ Choroby rzadkie Dermatologia Diabetologia Onkologia Neurologia Reumatologia Gastroenterologia Pulmonologia Ginekologia Kurier Medyczny Zalecenia i rekomendacje e-Praktyka Leczenia Ran Warto wiedzieć
e-Akademia
e-Akademia Zaburzeń Mikrobioty e-Akademia POChP e-Akademia Chorób Naczyń Akademia GLP-1
© 2025 Termedia Sp. z o.o.
Developed by Bentus.